These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 27337969)
1. Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity. Liu H; Wang H; Xiang D; Guo W Mini Rev Med Chem; 2017; 17(1):44-50. PubMed ID: 27337969 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer. Ghasemi K; Vaseghi G; Mansourian M J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570 [TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways. Wang A J; Zhang J; Xiao M; Wang S; Wang B J; Guo Y; Tang Y; Gu J Cell Mol Life Sci; 2021 Apr; 78(7):3105-3125. PubMed ID: 33438055 [TBL] [Abstract][Full Text] [Related]
4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Seymour L; Bramwell V; Moran LA Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762 [TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game. Dos Santos Arruda F; Tomé FD; Miguel MP; de Menezes LB; Nagib PRA; Campos EC; Soave DF; Celes MRN Curr Pharm Des; 2019; 25(2):109-118. PubMed ID: 30864503 [TBL] [Abstract][Full Text] [Related]
6. Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review. Fojtu M; Gumulec J; Stracina T; Raudenska M; Skotakova A; Vaculovicova M; Adam V; Babula P; Novakova M; Masarik M Curr Drug Metab; 2017; 18(3):237-263. PubMed ID: 28059036 [TBL] [Abstract][Full Text] [Related]
7. Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study. QuanJun Y; GenJin Y; LiLi W; YongLong H; Yan H; Jie L; JinLu H; Jin L; Run G; Cheng G PLoS One; 2017; 12(1):e0169567. PubMed ID: 28072830 [TBL] [Abstract][Full Text] [Related]
8. The Protective Role of Phenolic Compounds Against Doxorubicin-induced Cardiotoxicity: A Comprehensive Review. Razavi-Azarkhiavi K; Iranshahy M; Sahebkar A; Shirani K; Karimi G Nutr Cancer; 2016; 68(6):892-917. PubMed ID: 27341037 [TBL] [Abstract][Full Text] [Related]
9. Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2. Zhang S; Meng T; Liu J; Zhang X; Zhang J Medicine (Baltimore); 2015 Jan; 94(4):e445. PubMed ID: 25634181 [TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats. Pokrzywinski KL; Biel TG; Rosen ET; Bonanno JL; Aryal B; Mascia F; Moshkelani D; Mog S; Rao VA Biol Sex Differ; 2018 Jun; 9(1):25. PubMed ID: 29907135 [TBL] [Abstract][Full Text] [Related]
12. Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity. Monahan DS; Flaherty E; Hameed A; Duffy GP Biomed Pharmacother; 2021 Aug; 140():111702. PubMed ID: 34015579 [TBL] [Abstract][Full Text] [Related]
13. Alternative approach for mitigation of doxorubicin-induced cardiotoxicity using herbal agents. Khan MA; Singh M; Khan MS; Ahmad W; Najmi AK; Ahmad S Curr Clin Pharmacol; 2014; 9(3):288-97. PubMed ID: 23342982 [TBL] [Abstract][Full Text] [Related]
14. A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Ludke AR; Al-Shudiefat AA; Dhingra S; Jassal DS; Singal PK Can J Physiol Pharmacol; 2009 Oct; 87(10):756-63. PubMed ID: 19898559 [TBL] [Abstract][Full Text] [Related]
15. The Protective Effect of Natural Compounds on Doxorubicin-Induced Cardiotoxicity via Nicotinamide Adenine Dinucleotide Phosphate Oxidase Inhibition. Yousefian M; Hosseinzadeh H; Hayes AW; Hadizadeh F; Karimi G J Pharm Pharmacol; 2022 Mar; 74(3):351-359. PubMed ID: 34562089 [TBL] [Abstract][Full Text] [Related]
16. Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. Yu J; Wang C; Kong Q; Wu X; Lu JJ; Chen X Phytomedicine; 2018 Feb; 40():125-139. PubMed ID: 29496165 [TBL] [Abstract][Full Text] [Related]
17. Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity. Galal A; El-Bakly WM; Al Haleem EN; El-Demerdash E Cancer Chemother Pharmacol; 2016 Feb; 77(2):309-22. PubMed ID: 26676227 [TBL] [Abstract][Full Text] [Related]
18. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Reichardt P; Tabone MD; Mora J; Morland B; Jones RL Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541 [TBL] [Abstract][Full Text] [Related]
19. [Prevention against and treatment of doxorubicin-induced acute cardiotoxicity by dexrazoxane and schisandrin B]. Hu KY; Yang Y; He LH; Wang DW; Jia ZR; Li SR; Tian W; Mao J; Li XJ; Zhang W Yao Xue Xue Bao; 2014 Jul; 49(7):1007-12. PubMed ID: 25233631 [TBL] [Abstract][Full Text] [Related]
20. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]